Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Wang K, Sturt-Gillespie B, Hittle JC et al (2014) Thyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing protein. J Biol Chem 289(34):23928–23937. https://doi.org/10.1074/jbc.M114.585315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W, Zhang G, Li X et al (2018) Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun 499(3):416–424. https://doi.org/10.1016/j.bbrc.2018.03.129

Article  CAS  PubMed  Google Scholar 

San-Segundo PA, Roeder GS (1999) Pch2 links chromatin silencing to meiotic checkpoint control. Cell 97(3):313–324. https://doi.org/10.1016/s0092-8674(00)80741-2

Article  CAS  PubMed  Google Scholar 

Zhao L, Ye S, Jing S, Gao YJ, He T (2023) Targeting TRIP13 for overcoming anticancer drug resistance (review). Oncol Rep 50(5):202. https://doi.org/10.3892/or.2023.8639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banerjee R, Russo N, Liu M et al (2014) TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun 5:4527. https://doi.org/10.1038/ncomms5527

Article  CAS  PubMed  Google Scholar 

Marks DH, Thomas R, Chin Y, Shah R, Khoo C, Benezra R (2017) Mad2 overexpression uncovers a critical role for TRIP13 in mitotic exit. Cell Rep 19(9):1832–1845. https://doi.org/10.1016/j.celrep.2017.05.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu MX, Wei CY, Zhang PF et al (2019) Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res 38(1):443. https://doi.org/10.1186/s13046-019-1454-y

Article  PubMed  PubMed Central  Google Scholar 

Hu L, Shen D, Liang D et al (2020) Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth. Cancer Lett 493:156–166. https://doi.org/10.1016/j.canlet.2020.08.023

Article  CAS  PubMed  Google Scholar 

Zhang G, Zhu Q, Fu G et al (2019) TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br J Cancer 121(12):1069–1078. https://doi.org/10.1038/s41416-019-0633-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong L, Ding H, Li Y et al (2019) TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol 121:200–206. https://doi.org/10.1016/j.ijbiomac.2018.09.168

Article  CAS  PubMed  Google Scholar 

Lu W, Mengxuan Z, Ming R et al (2022) TRIP13/FLNA complex promotes tumor progression and is associated with unfavorable outcomes in melanoma. J Oncol 2022:1419179. https://doi.org/10.1155/2022/1419179

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue J, Wu H, Shi Y, Li Z (2023) TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration. Discov Oncol 14(1):176. https://doi.org/10.1007/s12672-023-00792-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu L, Gao Z, Cui Y, Yang X, Li H (2019) Thyroid receptor-interacting protein 13 is correlated with progression and poor prognosis in bladder cancer. Med Sci Monit 25:6660–6668. https://doi.org/10.12659/MSM.917112

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di S, Li M, Ma Z, Guo K, Li X, Yan X (2019) TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma. Pathol Res Pract 215(6):152415. https://doi.org/10.1016/j.prp.2019.04.007

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341. https://doi.org/10.1016/j.ijsu.2010.02.007

Article  PubMed  Google Scholar 

Li Z, Liu J, Chen T et al (2021) HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc. J Exp Clin Cancer Res 40(1):86. https://doi.org/10.1186/s13046-021-01890-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheng N, Yan L, Wu K et al (2018) TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis 9(3):402. https://doi.org/10.1038/s41419-018-0434-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni F, Liu X, Xia Y et al (2023) TRIP 13-dependent pathways promote the development of gastric cancer. Funct Integr Genomics 23(3):232. https://doi.org/10.1007/s10142-023-01160-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kowalewski A, Jaworski D, Antosik P et al (2020) TRIP13 predicts poor prognosis in clear cell renal cell carcinoma. Am J Cancer Res 10(9):2909–2918

CAS  PubMed  PubMed Central  Google Scholar 

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z

Article  PubMed  Google Scholar 

Rios Garcia M, Meissburger B, Chan J et al (2022) Trip13 depletion in liver cancer induces a lipogenic response contributing to Plin2-dependent mitotic cell death. Adv Sci (Weinh) 9(29):e2104291. https://doi.org/10.1002/advs.202104291

Article  CAS  PubMed  Google Scholar 

Tao Y, Yang G, Yang H et al (2017) TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 8(16):26718–26731. https://doi.org/10.18632/oncotarget.14957

Article  PubMed  PubMed Central  Google Scholar 

Zhang LT, Ke LX, Wu XY et al (2022) TRIP13 induces nedaplatin resistance in esophageal squamous cell carcinoma by enhancing repair of DNA damage and inhibiting apoptosis. Biomed Res Int 2022:7295458. https://doi.org/10.1155/2022/7295458

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afaq F, Agarwal S, Bajpai P et al (2024) Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Neoplasia 47:100951. https://doi.org/10.1016/j.neo.2023.100951

Article  CAS  PubMed  Google Scholar 

Agarwal S, Behring M, Kim HG et al (2020) TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Mol Oncol 14(12):3007–3029. https://doi.org/10.1002/1878-0261.12821

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal S, Afaq F, Bajpai P et al (2022) DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer. Mol Oncol 16(8):1728–1745. https://doi.org/10.1002/1878-0261.13201

Article